Navigation Links
Sangamo BioSciences to Present at the BMO Capital Markets Health Care Conference
Date:11/30/2007

RICHMOND, Calif., Nov. 30 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that Edward Lanphier, Sangamo's president and CEO, will provide an update on the progress of Sangamo's ZFP Therapeutic development programs and an overview of the company's business strategy at 3:00 pm (ET) on Tuesday, December 4, 2007 at the BMO Capital Markets Focus on Health Care Conference in New York.

The presentation will be webcast live and may be accessed via a link on the Sangamo BioSciences website in the Investor Relations section http://investor.sangamo.com/index.cfm under Events and Presentations. The presentation will be archived on the Sangamo website for two weeks after the event.

About Sangamo

Sangamo BioSciences, Inc. is focused on the research and development of novel DNA-binding proteins for therapeutic gene regulation and modification. The most advanced ZFP Therapeutic(TM) development program is currently in Phase 2 clinical trials for evaluation of safety and clinical effect in patients with diabetic neuropathy. Phase 1 clinical trials are ongoing to evaluate a ZFP Therapeutic for peripheral artery disease. Other therapeutic development programs are focused on cancer and HIV/AIDS, neuropathic pain, nerve regeneration, Parkinson's disease and monogenic diseases. Sangamo's core competencies enable the engineering of a class of DNA-binding proteins known as zinc finger DNA-binding proteins (ZFPs). By engineering ZFPs that recognize a specific DNA sequence Sangamo has created ZFP transcription factors (ZFP TF(TM)) that can control gene expression and, consequently, cell function. Sangamo is also developing s
'/>"/>

SOURCE Sangamo BioSciences, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Sangamo BioSciences Presents Data Demonstrating In Vivo Protection Against HIV Infection by CCR5-ZFN Therapeutic
2. Sangamo BioSciences to Present at the UBS Global Life Sciences Conference
3. Sangamo BioSciences to Present at the 2007 BIO InvestorForum
4. Sangamo BioSciences Announces Third Quarter 2007 Conference Call and Webcast
5. Sangamo BioSciences Announces ZFP Therapeutic Data From Nerve Regeneration Program at Society for Neuroscience Meeting
6. Sangamo BioSciences to Present at the Piper Jaffray Health Care Conference
7. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
8. Selection of Development Candidate Triggers $0.5 Million Milestone Payment to Ardea Biosciences, Inc.
9. ImmuneRegen BioSciences Files 8-K that Highlights Enclosed Shareholder Letter Discussing Recent Achievements and Outlook
10. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
11. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)...hfirmReplikinsLtd.,whichhasanalyzedtheH1N1virus,ge...utbreak,andprogressofthecurrentH1N1pandemic,todayi...datashowsthatthelethalityoftheH1N1("SwineFlu")viru...,scurrentoutbreakinthespringof2009torestingnon-epi...ectivitycount,however,remainsincreased. ,, Then...
(Date:11/25/2009)...tlinker.comannouncesthatanewmarketresearchreportis...rketAnalysisandForecaststo2013 ,, http://www....-Analysis-and-Forecasts-to-2013.html ,, Brazil...Summary ,, Thereportprovidesdetailedanalysisan...ioethanolmarketinparticular.Italsohelpsinanalyzing...
(Date:11/24/2009)...vestment bank KTA Capital,s client Neuren Pharmace...vertible note private placement with a U.S. instit...ed by KTA Capital as Neuren,s exclusive placement ...York (PRWEB) November 23, 2009 -- The independent ...TA Capital") has announced that its client Ne...
(Date:11/24/2009)...ployment grew by 29,000 jobs in October, and the ...th during the U.S. recession. However, clinics and... systems are coming closer to having to actually c...rs. , (Vocus) November 24... in October despite the shedding of jobs in most o...
Breaking Biology Technology:Biological H1N1 Vaccines: Too Little, Too Late 2Biological H1N1 Vaccines: Too Little, Too Late 3Biological H1N1 Vaccines: Too Little, Too Late 4Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 2Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 3Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 4Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 5Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 6Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 7Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 8Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 9KTA Capital Arranges an AU$6.7 Million Private Placement by Neuren Pharmaceuticals 2The MedZilla Report for October 2009 - Health Care Employment Grows Again in October Even As Clinics, Specialty Centers Close 2The MedZilla Report for October 2009 - Health Care Employment Grows Again in October Even As Clinics, Specialty Centers Close 3The MedZilla Report for October 2009 - Health Care Employment Grows Again in October Even As Clinics, Specialty Centers Close 4
... ev3 Inc. (Nasdaq:,EVVV) will release its 2007 fo...iday, February 22, 2008, before regular market tra...all and webcast the same day at,7:30 a.m. CT (8:30...uarter,and full-year financial and operating resul...answer session., The conference call will be avai...
...FORD, England, February 8 /PRNewswire-FirstCall/,-...announced that Jörn,Aldag, President & CEO, will p... York., Date: Tuesday, 12 February 2008 ...MT) Location: Waldorf-Astoria, New York City, ...Evotec website at, http://www.evotec.com - Invest...
...ilable in Spanish . , ANN ARBOR, Mich.---A new ...ectricity from walking to operate a portable GPS l... or an implanted neurotransmitter, research involv...on the device is published in the Feb. 8 issue of ...rom Simon Fraser University in Canada and the Univ...
Other Biology Technology:ev3 Inc. to Report 2007 Fourth Quarter and Full-Year Financial Results and Host Conference Call on February 22, 2008 2Knee brace generates electricity from walking 2
(Date:11/25/2009)...Ghrelin, a hormone produced in the stomach, may be...ment of Parkinson,s disease, Yale School of Medici...cent issue of the Journal of Neuroscience . , P...dopamine neurons in an area of the midbrain known ...dopamine production. Reduced production of dopami...
(Date:11/25/2009)...On September 11, firefighters, police officers and...t in the World Trade Center complex. They battled ...arched for survivors, tackled fires and evacuated ...ained an estimated 17,000 people. And making their...ations: frightened workers and their relatives jam...
(Date:11/25/2009)...MADISON, WI, NOVEMBER 25, 2009 Soil is the linchp..., and hydrosphere meet. Despite that, many student... but nothing more. Soil science educators are chal...ublic recognize the critical importance of soil in...soil science and earth science teachers at Univers...
Breaking Biology News(10 mins):Hormone ghrelin can boost resistance to Parkinson's disease 2Magic box for mission impossible 2Magic box for mission impossible 3It's not just dirt! 2Brain Protein Tied to Retardation 59897 1Informed Consent Goes Mobile Helping Patients and Clinicians Cut Confusion and Paperwork 59894 1Informed Consent Goes Mobile Helping Patients and Clinicians Cut Confusion and Paperwork 59894 2Informed Consent Goes Mobile Helping Patients and Clinicians Cut Confusion and Paperwork 59894 3Lake Health Celebrates Grand Opening of TriPoint Medical Center 59890 1Lake Health Celebrates Grand Opening of TriPoint Medical Center 59890 2Lake Health Celebrates Grand Opening of TriPoint Medical Center 59890 3Lake Health Celebrates Grand Opening of TriPoint Medical Center 59890 4Lake Health Celebrates Grand Opening of TriPoint Medical Center 59890 5Lake Health Celebrates Grand Opening of TriPoint Medical Center 59890 6Lake Health Celebrates Grand Opening of TriPoint Medical Center 59890 7
... novel delivery system that could lead to more eff...infectious diseases has been developed by biomedic... , The findings use specific ribonucleic acid (RN...effectiveness while tailoring it based on the type...articular disease, says Krishnendu Roy, associate ...
... available in German . , The cause of diseases... in humans is a prion protein. This protein attach...ugar and lipid components (a glycosylphosphatidyli...seems to have a strong influence on the transforma...thogenic form, which causes scrapie and mad cow di...
...RBOR, N.Y. (Oct. 7, 2008) A new, user-friendly l...ysis has just been released by Cold Spring Harbor ...y use in the laboratory, it includes essential ste..., recommended experimental strategies, and trouble...lated methods used by scientists at all levels. , ...
Other Biology News:RNA molecules, delivery system improve vaccine responses, effectiveness 2Tracking down the cause of mad cow disease 2New lab manual focuses on essential methods for purifying and characterizing proteins 2
Anti-Human Aminopeptidase P2 / XPNPEP2 Affinity Purified Polyclonal Antibody, Unconjugated from R&D Systems
Amino Acid Mixture Minus Cysteine from Promega
Quant-iT RiboGreen RNA Assay Kit from Molecular Probes (Invitrogen)
Donor Horse Serum from Lifeblood Medical, Inc.
Biology Products: